EC-Logo-2018_TM_CMYK.jpg
electroCore Announces Second Quarter 2023 Financial Results
August 09, 2023 16:05 ET | electroCore, Inc.
Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter 2022 Company to host a conference call and webcast today, August 9, 2023 at 4:30 PM EDT ...
EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
July 18, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
EC-Logo-2018_TM_CMYK.jpg
electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC
July 13, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that ReletexTM by Reliefband,...
EC-Logo-2018_TM_CMYK.jpg
electroCore Provides Select Second Quarter 2023 Financial Guidance
July 11, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., July 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today provided select preliminary...
EC-Logo-2018_TM_CMYK.jpg
gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms
July 06, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., July 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its gammaCore non-invasive...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at 13th Annual LD Micro Invitational XIII
May 23, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces First Quarter 2023 Financial Results
May 03, 2023 16:01 ET | electroCore, Inc.
Record first quarter 2023 net sales of $2.8 million, approximately 46% over first quarter 2022 Company to host a conference call and webcast today, May 3, 2023, at 4:30 PM EDT ROCKAWAY, N.J., May ...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Annual Aegis Virtual Conference
May 01, 2023 16:01 ET | electroCore, Inc.
ROCKAWAY, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning
April 24, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the Air Force Research...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
April 12, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue...